Rift Valley Fever
11
2
4
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (11)
Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)
Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)
A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults
Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated
RVF and Other Emerging Infectious Diseases in East and Central Africa
Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine
Safety and Immunogenicity Study of Rift Valley Fever Vaccine
Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine
Rift Valley Fever in Kenya